Search

Your search keyword '"Bearz, Alessandra"' showing total 444 results
Start Over Author "Bearz, Alessandra"
444 results on '"Bearz, Alessandra"'

4. Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations

Author

Bearz, Alessandra, Martini, Jean-François, Jassem, Jacek, Kim, Sang-We, Chang, Gee-Chen, Shaw, Alice T., Shepard, Deborah A., Dall’O’, Elisa, Polli, Anna, Thurm, Holger, Zalcman, Gerard, Garcia Campelo, Maria Rosario, Penkov, Konstantin, Hayashi, Hidetoshi, and Solomon, Benjamin J.

Published
2023
Full Text
View/download PDF

5. Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2)

Author

Ou, Sai-Hong Ignatius, Nishio, Makoto, Ahn, Myung-Ju, Mok, Tony, Barlesi, Fabrice, Zhou, Caicun, Felip, Enriqueta, de Marinis, Filippo, Kim, Sang-We, Pérol, Maurice, Liu, Geoffrey, Migliorino, Maria Rita, Kim, Dong-Wan, Novello, Silvia, Bearz, Alessandra, Garrido, Pilar, Mazieres, Julien, Morabito, Alessandro, Lin, Huamao M., Yang, Hui, Niu, Huifeng, Zhang, Pingkuan, and Kim, Edward S.

Published
2022
Full Text
View/download PDF

7. Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial

Author

Kindler, Hedy L, Novello, Silvia, Bearz, Alessandra, Ceresoli, Giovanni L, Aerts, Joachim G J V, Spicer, James, Taylor, Paul, Nackaerts, Kristiaan, Greystoke, Alastair, Jennens, Ross, Calabrò, Luana, Burgers, Jacobus A, Santoro, Armando, Cedrés, Susana, Serwatowski, Piotr, Ponce, Santiago, Van Meerbeeck, Jan P, Nowak, Anna K, Blumenschein, George, Jr, Siegel, Jonathan M, Kasten, Linda, Köchert, Karl, Walter, Annette O, Childs, Barrett H, Elbi, Cem, Hassan, Raffit, and Fennell, Dean A

Published
2022
Full Text
View/download PDF

9. CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non–Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy

Author

Neal, Joel, primary, Pavlakis, Nick, additional, Kim, Sang-We, additional, Goto, Yasushi, additional, Lim, Sun Min, additional, Mountzios, Giannis, additional, Fountzilas, Elena, additional, Mochalova, Anastasia, additional, Christoph, Daniel C., additional, Bearz, Alessandra, additional, Quantin, Xavier, additional, Palmero, Ramon, additional, Antic, Vladan, additional, Chun, Elaine, additional, Edubilli, Tirupathi Rao, additional, Lin, Ya-Chen, additional, Huseni, Mahrukh, additional, Ballinger, Marcus, additional, Graupner, Vilma, additional, Curran, Dominic, additional, Vervaet, Piet, additional, and Newsom-Davis, Thomas, additional

Published
2024
Full Text
View/download PDF

10. Radical Hemithoracic Radiotherapy Versus Palliative Radiotherapy in Non-metastatic Malignant Pleural Mesothelioma: Results from a Phase 3 Randomized Clinical Trial

Author

Trovo, Marco, Relevant, Alberto, Polesel, Jerry, Muraro, Elena, Barresi, Loredana, Drigo, Annalisa, Baresic, Tanja, Bearz, Alessandra, Fanetti, Giuseppe, Del Conte, Alessandro, Matrone, Fabio, Reverberi, Chiara, Furlan, Carlo, Zuccon, Umberto, Fontana, Paolo, Franchin, Giovanni, and Minatel, Emilio

Published
2021
Full Text
View/download PDF

11. Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial

Author

Bria, Emilio, Morgillo, Floriana, Garassino, Marina Chiara, Ciardiello, Fortunato, Ardizzoni, Andrea, Stefani, Alessio, Verderame, Francesco, Morabito, Alessandro, Chella, Antonio, Tonini, Giuseppe, Gilli, Marina, Del Signore, Ester, Berardi, Rossana, Mencoboni, Manlio, Bearz, Alessandra, Delmonte, Angelo, Migliorino, Marta Rita, Gridelli, Cesare, Pazzola, Antonio, Iero, Manuela, De Marinis, Filippo, Bria, Emilio (ORCID:0000-0002-2333-704X), Bria, Emilio, Morgillo, Floriana, Garassino, Marina Chiara, Ciardiello, Fortunato, Ardizzoni, Andrea, Stefani, Alessio, Verderame, Francesco, Morabito, Alessandro, Chella, Antonio, Tonini, Giuseppe, Gilli, Marina, Del Signore, Ester, Berardi, Rossana, Mencoboni, Manlio, Bearz, Alessandra, Delmonte, Angelo, Migliorino, Marta Rita, Gridelli, Cesare, Pazzola, Antonio, Iero, Manuela, De Marinis, Filippo, and Bria, Emilio (ORCID:0000-0002-2333-704X)

Abstract

Background MAURIS is an Italian multicenter, open-label, phase IIIb ongoing trial, aiming at evaluating the safety and effectiveness of atezolizumab + carboplatin/etoposide in patients with newly diagnosed, extensive-stage small-cell lung cancer (ES-SCLC). The primary objective is the safety evaluation.Materials and Methods Patients received atezolizumab + carboplatin/etoposide Q3W for 4-6 cycles in the induction phase, followed by atezolizumab maintenance Q3W. We presented the interim analysis on safety (referring to the induction phase) and clinical effectiveness, in all patients (N = 154) and in subgroups that received <= 3 (N = 23), 4 (N = 43), and 5-6 cycles (N = 89) of induction.Results At a median follow-up of 10.5 months, 139 patients (90.3%) discontinued treatment. Serious adverse events occurred in 29.9% of patients overall, and the rate was lower in patients with 5-6 cycles (19.1%) than in those with 4 (34.9%) or <= 3 (63.6%) cycles. Immune-mediated adverse events were reported in 14.9%, 15.7%, 11.6%, and 18.2% of patients, overall and by subgroup, respectively. The median overall survival and progression-free survival were 10.7 and 5.5 months, respectively. Overall, 111 patients (71.6%) had a tumor response.Conclusions Interim results provide further evidences about safety and efficacy profile of atezolizumab + carboplatin/etoposide treatment in a ES-SCLC patient population closer to that observed in clinical practice.Clinical Trial Registration Eudract No. 2019-001146-17, NCT04028050.This analysis is based on interim data from the MAURIS study, an Italian multicenter, phase IIIb ongoing trial to evaluate treatment with atezolizumab plus carboplatin/etoposide in patients with newly diagnosed extensive-stage small-cell lung cancer.

Published
2024

12. Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial

Author

Bria, Emilio, primary, Morgillo, Floriana, additional, Garassino, Marina Chiara, additional, Ciardiello, Fortunato, additional, Ardizzoni, Andrea, additional, Stefani, Alessio, additional, Verderame, Francesco, additional, Morabito, Alessandro, additional, Chella, Antonio, additional, Tonini, Giuseppe, additional, Gilli, Marina, additional, Del Signore, Ester, additional, Berardi, Rossana, additional, Mencoboni, Manlio, additional, Bearz, Alessandra, additional, Delmonte, Angelo, additional, Migliorino, Marta Rita, additional, Gridelli, Cesare, additional, Pazzola, Antonio, additional, Iero, Manuela, additional, and De Marinis, Filippo, additional

Published
2024
Full Text
View/download PDF

15. Is multidisciplinary management possible in the treatment of lung cancer? A report from three Italian meetings

Author

Franceschini, Davide, Bruni, Alessio, Borghetti, Paolo, Giaj-Levra, Niccolò, Ramella, Sara, Buffoni, Lucio, Badellino, Serena, Andolina, Maria, Comin, Camilla, Vattemi, Emanuela, Bezzi, Michela, Trovò, Marco, Passaro, Antonio, Bearz, Alessandra, Chiari, Rita, Tindara, Franchina, Ferrari, Katia, Piperno, Gaia, Filippi, Andrea Riccardo, Genovesi, Domenico, and Scotti, Vieri

Published
2020
Full Text
View/download PDF

16. Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study

Author

Procopio, Giuseppe, Apollonio, Giulia, Cognetti, Francesco, Miceli, Rosalba, Milella, Michele, Mosca, Alessandra, Chiuri, Vincenzo Emanuele, Bearz, Alessandra, Morelli, Franco, Ortega, Cinzia, Atzori, Francesco, Donini, Maddalena, Ratta, Raffaele, Raimondi, Alessandra, Claps, Melanie, Martinetti, Antonia, Capitanio, Umberto, de Braud, Filippo G., Cappelletti, Vera, and Verzoni, Elena

Published
2019
Full Text
View/download PDF

17. Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)–Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study

Author

Cho, Byoung Chul, Obermannova, Radka, Bearz, Alessandra, McKeage, Mark, Kim, Dong-Wang, Batra, Ullas, Borra, Gloria, Orlov, Sergey, Kim, Sang-We, Geater, Sarayut L., Postmus, Pieter E., Laurie, Scott A., Park, Keunchil, Yang, Cheng-Ta, Ardizzoni, Andrea, Bettini, Anna C., de Castro, Gilberto, Jr., Kiertsman, Flavia, Chen, Zhe, Lau, Yvonne Y., Viraswami-Appanna, Kalyanee, Passos, Vanessa Q., and Dziadziuszko, Rafal

Published
2019
Full Text
View/download PDF

19. Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study

Author

Pilotto, Sara, Rossi, Antonio, Vavalà, Tiziana, Follador, Alessandro, Tiseo, Marcello, Galetta, Domenico, Morabito, Alessandro, Di Maio, Massimo, Martelli, Olga, Caffo, Orazio, Piovano, Pier Luigi, Cortinovis, Diego, Zilembo, Nicoletta, Casartelli, Clelia, Banna, Giuseppe Luigi, Ardizzoia, Antonio, Barzelloni, Maria Luisa, Bearz, Alessandra, Genestreti, Giovenzio, Mucciarini, Claudia, Filipazzi, Virginio, Menis, Jessica, Rizzo, Elisa, Barbieri, Fausto, Rijavec, Erika, Cecere, Fabiana, Spitaleri, Gianluca, Bria, Emilio, and Novello, Silvia

Published
2018
Full Text
View/download PDF

22. ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)

Author

Cho, Byoung Chul, Kim, Dong-Wan, Bearz, Alessandra, Laurie, Scott A., McKeage, Mark, Borra, Gloria, Park, Keunchil, Kim, Sang-We, Ghosn, Marwan, Ardizzoni, Andrea, Maiello, Evaristo, Greystoke, Alastair, Yu, Richard, Osborne, Karen, Gu, Wen, Scott, Jeffrey W., Passos, Vanessa Q., Lau, Yvonne Y., and Wrona, Anna

Published
2017
Full Text
View/download PDF

23. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

Author

Shaw, Alice T, Kim, Tae Min, Crinò, Lucio, Gridelli, Cesare, Kiura, Katsuyuki, Liu, Geoffrey, Novello, Silvia, Bearz, Alessandra, Gautschi, Oliver, Mok, Tony, Nishio, Makoto, Scagliotti, Giorgio, Spigel, David R, Deudon, Stéphanie, Zheng, Cheng, Pantano, Serafino, Urban, Patrick, Massacesi, Cristian, Viraswami-Appanna, Kalyanee, and Felip, Enriqueta

Published
2017
Full Text
View/download PDF

24. Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer.

Author

Chen, Joseph, Bearz, Alessandra, Kim, Dong-Wan, Mamdani, Hirva, Bauman, Jessica, Chiari, Rita, Ou, Sai-Hong Ignatius, Solomon, Benjamin J., Soo, Ross A., Felip, Enriqueta, Shaw, Alice T., Thurm, Holger, Clancy, Jill S., Lee, Kimberly, O'Gorman, Melissa, Tanski, Cherie, and Pithavala, Yazdi K.

Subjects
*ANAPLASTIC lymphoma kinase, *NON-small-cell lung carcinoma, *PHARMACOKINETICS, *P-glycoprotein, *PROTEIN-tyrosine kinase inhibitors, *CYTOCHROME P-450
Abstract

Background and Objective: Lorlatinib is a tyrosine kinase inhibitor approved for the treatment of advanced anaplastic lymphoma kinase–positive non-small cell lung cancer. This study assessed the effect of steady-state lorlatinib on the metabolic enzymes cytochrome P450 (CYP) 2B6, CYP2C9, and uridine 5′-diphospho-glucuronosyltransferase (UGT) and the P-glycoprotein (P-gp) transporter. Methods: Thirty-two patients received a single oral dose of a probe drug on Day − 2 to determine the pharmacokinetics of the probe drug alone. Starting on Day 1, patients received 100 mg oral lorlatinib daily. On Day 15, a single oral dose of the probe drug was administered concurrently with lorlatinib. Pharmacokinetic parameters for these probe substrates were assessed. Results: Plasma exposures of all probe substrates were reduced by lorlatinib compared with the probe alone. The greatest reduction in area under the plasma concentration–time curve from time zero to infinity (AUC∞) and maximum (peak) plasma drug concentration (Cmax) (67% and 63% decrease, respectively) was observed with the P-gp probe substrate fexofenadine. Lorlatinib coadministration also decreased the AUC∞ and Cmax of bupropion (CYP2B6 probe substrate) by 25% and 27%, tolbutamide (CYP2C9 probe substrate) by 43% and 15%, and acetaminophen (UGT probe substrate) by 45% and 28%, respectively. Conclusions: Lorlatinib is a net moderate inducer of P-gp and a weak inducer of CYP2B6, CYP2C9, and UGT after steady state is achieved with daily dosing. Medications that are P-gp substrates with a narrow therapeutic window should be avoided in patients taking lorlatinib; no dose modifications are needed with substrates of CYP2B6, CYP2C9, or UGT. ClinicalTrials.gov: NCT01970865. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

Author

Ignatius Ou, SaiHong, Planchard, David, Park, Keunchil, Schuler, Martin, Yang, James, Chand, Vikram, Rohr, Klaus, Bagnes, Claudia, Martin, Claudio Marcelo, Recondo, Gonzalo, Zarba, Juan Jose, Blajman, Cesar, Richardet, Martín, McLachlan, Sue-Anne, Parente, Phillip, Underhill, Craig, Crombie, Catherine, Mainwaring, Paul, Greil, Richard, Humblet, Yves, Bustin, Frédérique, Carestia, Luciano, Galdermans, Danny, Lambrechts, Marc, Delval, Laetitia, Vercauter, Piet, Zhou, Caicun, Wang, Jin, Huang, Cheng, Lin, Xiaoyan, Wu, Yilong, Liu, Xiaoqing, Cheng, Ying, Qin, Shukui, Feng, Jifeng, Huang, Jianjin, Zhang, Yiping, Lu, Shun, Zereu, Manuela, Garicochea, Bernardo, Zadra, Cyntia Albuquerque, Riska, Henrik, Alanko, Tuomo, Cadranel, Jacques, Chouaid, Christos, Zalcman, Gérard, Sibilot, Denis Moro, Perol, Maurice, Bennouna, Jaafar, Fournel, Pierre, Gervais, Radj, Rotarski, Maciej, Coudert, Bruno, Thomas, Michael, Wehler, Thomas, Faehling, Martin, Keilholz, Ulrich, Laack, Eckart, von Pawel, Joachim, Huber, Rudolf, Dickgreber, Nicolas, Wiewrodt, Rainer, Mark, Zsuzsanna, Tehenes, Sandor, Strausz, Janos, Sarosi, Veronika, Prabhash, Kumar, Jain, Minish, Venkatesan, Srinivasan, Sharma, Lalit, Dadhich, Hemant, Nagarkar, Rajnish Vasant, Onn, Amir, Gottfried, Maya, Stemmer, Solomon, Migliorino, Maria Rita, Grossi, Francesco, Bidoli, Paolo, Bearz, Alessandra, Gridelli, Cesare, Milandri, Carlo, Platania, Marco, Ceresoli, Giovanni Luca, Cruciani, Giorgio, Delgado, Francisco Gutierrez, Gonzalez Perez, José Luis, Luna, Gabriela Alvarado, Baca, Othon Padilla, Aerts, J.G.J.V., Stigt, J.A., Dingemans, A.M.C., Herder, G.J.M., Gans, S.J.M., Salas Sánchez, Jorge Fernando, Alvarez Barreda, Renzo Luzgardo, Pantigoso, Wilbert Rodriguez, Palomino, Osbert Luis Mejia, Jaskiewicz, Piotr, Kazarnowicz, Andrzej, Serwatowski, Piotr, Szczesna, Aleksandra, Jassem, Jacek, Lubennikov, Vladimir, Karaseva, Nina, Orlov, Sergey, Ragulin, Yuri, Garrido, Pilar, González Larriba, José Luis, Camps, Carlos, Campelo, Rosario García, Lianes, Pilar, Cobo, Manuel, Felip, Enriqueta, Kim, Dong-Wan, Kim, Sang-We, Kim, Joo-Hang, Han, Ji-Youn, Kim, Young-Chul, Yang, Chih-Hsin, Hsia, Te-Chun, Chen, Yuh-Min, Tsai, Ying-Huang, Chang, Gee-Chen, Tsao, Thomas Chang-Yao, Su, Wu-Chou, Huang, Ming-Shyan, Ho, Ching-Liang, Hsieh, Ruey-Kuen, Vinnyk, Yuriy, Popovych, Oleksandr, Ponomarova, Olga, Bondarenko, Igor, Polishchuk, Iryna, Shah, Riyaz, Mitra, Sanka, Popat, Sanjaykumar, Spicer, James, Toy, Elizabeth, Talbot, Toby, Brown, Emma, Upadhyay, Sunil, Summers, Yvonne, Gurtler, Jayne, Meza, Luis, Thropay, John, Schuler, M., Yang, J.C.-H., Park, K., Kim, J.-H., Bennouna, J., Chen, Y.-M., Chouaid, C., De Marinis, F., Feng, J.-F., Grossi, F., Kim, D.-W., Liu, X., Lu, S., Strausz, J., Vinnyk, Y., Wiewrodt, R., Zhou, C., Wang, B., Chand, V.K., and Planchard, D.

Published
2016
Full Text
View/download PDF

29. Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non–Small-Cell Lung Cancer From the Phase III CROWN Study

Author

Solomon, Benjamin J., primary, Bauer, Todd M., additional, Ignatius Ou, Sai-Hong, additional, Liu, Geoffrey, additional, Hayashi, Hidetoshi, additional, Bearz, Alessandra, additional, Penkov, Konstantin, additional, Wu, Yi-Long, additional, Arrieta, Oscar, additional, Jassem, Jacek, additional, Calella, Anna M., additional, Peltz, Gerson, additional, Polli, Anna, additional, Thurm, Holger, additional, and Mok, Tony, additional

Published
2022
Full Text
View/download PDF

30. Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial

Author

Gregorc, Vanesa, Novello, Silvia, Lazzari, Chiara, Barni, Sandro, Aieta, Michele, Mencoboni, Manlio, Grossi, Francesco, Pas, Tommaso De, de Marinis, Filippo, Bearz, Alessandra, Floriani, Irene, Torri, Valter, Bulotta, Alessandra, Cattaneo, Angela, Grigorieva, Julia, Tsypin, Maxim, Roder, Joanna, Doglioni, Claudio, Levra, Matteo Giaj, Petrelli, Fausto, Foti, Silvia, Viganò, Mariagrazia, Bachi, Angela, and Roder, Heinrich

Published
2014
Full Text
View/download PDF

32. Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALKVariant Type and ALKWith or Without TP53Mutations

Author

Bearz, Alessandra, Martini, Jean-François, Jassem, Jacek, Kim, Sang-We, Chang, Gee-Chen, Shaw, Alice T., Shepard, Deborah A., Dall’O’, Elisa, Polli, Anna, Thurm, Holger, Zalcman, Gerard, Garcia Campelo, Maria Rosario, Penkov, Konstantin, Hayashi, Hidetoshi, and Solomon, Benjamin J.

Abstract

Lorlatinib, a third-generation ALK tyrosine kinase inhibitor, improved outcomes compared with crizotinib in patients with previously untreated ALK-positive advanced NSCLC in the phase 3 CROWN study. Here, we investigated response correlates using plasma circulating tumor DNA (ctDNA) and tumor tissue profiling.

Published
2023
Full Text
View/download PDF

40. Phase 3 trial of lorlatinib in treatment-naive patients (Pts) with ALK-positive advanced non–small cell lung cancer (NSCLC): Comprehensive plasma and tumor genomic analyses.

Author

Bearz, Alessandra, primary, Martini, Jean-Francois, additional, Jassem, Jacek, additional, Kim, Sang-We, additional, Chang, Gee-Chen, additional, Shaw, Alice Tsang, additional, Shepard, Deborah, additional, Dall’O, Elisa, additional, Polli, Anna, additional, Thurm, Holger C., additional, Zalcman, Gerard, additional, Campelo, Rosario Garcia, additional, Penkov, Konstantin, additional, Hayashi, Hidetoshi, additional, and Solomon, Benjamin J., additional

Published
2022
Full Text
View/download PDF

42. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Author

Rosell, Rafael, Carcereny, Enric, Gervais, Radj, Vergnenegre, Alain, Massuti, Bartomeu, Felip, Enriqueta, Palmero, Ramon, Garcia-Gomez, Ramon, Pallares, Cinta, Sanchez, Jose Miguel, Porta, Rut, Cobo, Manuel, Garrido, Pilar, Longo, Flavia, Moran, Teresa, Insa, Amelia, De Marinis, Filippo, Corre, Romain, Bover, Isabel, Illiano, Alfonso, Dansin, Eric, de Castro, Javier, Milella, Michele, Reguart, Noemi, Altavilla, Giuseppe, Jimenez, Ulpiano, Provencio, Mariano, Moreno, Miguel Angel, Terrasa, Josefa, Muñoz-Langa, Jose, Valdivia, Javier, Isla, Dolores, Domine, Manuel, Molinier, Olivier, Mazieres, Julien, Baize, Nathalie, Garcia-Campelo, Rosario, Robinet, Gilles, Rodriguez-Abreu, Delvys, Lopez-Vivanco, Guillermo, Gebbia, Vittorio, Ferrera-Delgado, Lioba, Bombaron, Pierre, Bernabe, Reyes, Bearz, Alessandra, Artal, Angel, Cortesi, Enrico, Rolfo, Christian, Sanchez-Ronco, Maria, Drozdowskyj, Ana, Queralt, Cristina, de Aguirre, Itziar, Ramirez, Jose Luis, Sanchez, Jose Javier, Molina, Miguel Angel, Taron, Miquel, and Paz-Ares, Luis

Published
2012
Full Text
View/download PDF

43. Prospective phase II study of sunitinib rechallenge in metastatic renal cell carcinoma: The “retry” study from the Italian Group of Onco-Nephrology (G.I.O.N.)

Author

Porta, Camillo, primary, Ferrari, Vittorio, additional, Zucali, Paolo A., additional, Fornarini, Giuseppe, additional, Bernardo, Antonio, additional, Falconeri, Andrea, additional, Santarossa, Sandra, additional, Tinelli, Carmine, additional, Rizzo, Mimma, additional, Pappagallo, Giovanni, additional, and Bearz, Alessandra, additional

Published
2022
Full Text
View/download PDF

44. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

Author

Schuler, M., Yang, J. C.-H., Park, K., Kim, J.-H., Bennouna, J., Chen, Y.-M., Chouaid, C., De Marinis, F., Feng, J.-F., Grossi, F., Kim, D.-W., Liu, X., Lu, S., Strausz, J., Vinnyk, Y., Wiewrodt, R., Zhou, C., Wang, B., Chand, V. K., Planchard, D., Ignatius Ou, Sai Hong, Planchard, David, Park, Keunchil, Schuler, Martin, Yang, James, Chand, Vikram, Rohr, Klaus, Bagnes, Claudia, Martin, Claudio Marcelo, Recondo, Gonzalo, Zarba, Juan Jose, Blajman, Cesar, Richardet, Martín, McLachlan, Sue-Anne, Parente, Phillip, Underhill, Craig, Crombie, Catherine, Mainwaring, Paul, Greil, Richard, Humblet, Yves, Bustin, Frédérique, Carestia, Luciano, Galdermans, Danny, Lambrechts, Marc, Delval, Laetitia, Vercauter, Piet, Zhou, Caicun, Wang, Jin, Huang, Cheng, Lin, Xiaoyan, Wu, Yilong, Liu, Xiaoqing, Cheng, Ying, Qin, Shukui, Feng, Jifeng, Huang, Jianjin, Zhang, Yiping, Lu, Shun, Zereu, Manuela, Garicochea, Bernardo, Zadra, Cyntia Albuquerque, Riska, Henrik, Alanko, Tuomo, Cadranel, Jacques, Chouaid, Christos, Zalcman, Gérard, Sibilot, Denis Moro, Perol, Maurice, Planchard, David, Bennouna, Jaafar, Fournel, Pierre, Gervais, Radj, Rotarski, Maciej, Coudert, Bruno, Schuler, Martin, Thomas, Michael, Wehler, Thomas, Faehling, Martin, Keilholz, Ulrich, Laack, Eckart, von Pawel, Joachim, Huber, Rudolf, Dickgreber, Nicolas, Wiewrodt, Rainer, Mark, Zsuzsanna, Tehenes, Sandor, Strausz, Janos, Sarosi, Veronika, Prabhash, Kumar, Jain, Minish, Venkatesan, Srinivasan, Sharma, Lalit, Dadhich, Hemant, Nagarkar, Rajnish Vasant, Onn, Amir, Gottfried, Maya, Stemmer, Solomon, Migliorino, Maria Rita, Grossi, Francesco, Bidoli, Paolo, Bearz, Alessandra, Gridelli, Cesare, Milandri, Carlo, Platania, Marco, Ceresoli, Giovanni Luca, Cruciani, Giorgio, Delgado, Francisco Gutierrez, Gonzalez Perez, José Luis, Luna, Gabriela Alvarado, Baca, Othon Padilla, Aerts, J.G.J.V., Stigt, J.A., Dingemans, A.M.C., Herder, G.J.M., Gans, S. J. M., Salas Sánchez, Jorge Fernando, Alvarez Barreda, Renzo Luzgardo, Pantigoso, Wilbert Rodriguez, Palomino, Osbert Luis Mejia, Jaskiewicz, Piotr, Kazarnowicz, Andrzej, Serwatowski, Piotr, Szczesna, Aleksandra, Jassem, Jacek, Lubennikov, Vladimir, Karaseva, Nina, Orlov, Sergey, Ragulin, Yuri, Garrido, Pilar, González Larriba, José Luis, Camps, Carlos, Campelo, Rosario García, Lianes, Pilar, Cobo, Manuel, Felip, Enriqueta, Kim, Dong-Wan, Kim, Sang-We, Park, Keunchil, Kim, Joo-Hang, Han, Ji-Youn, Kim, Young-Chul, Yang, Chih-Hsin, Hsia, Te-Chun, Chen, Yuh-Min, Tsai, Ying-Huang, Chang, Gee-Chen, Tsao, Thomas Chang-Yao, Su, Wu-Chou, Huang, Ming-Shyan, Ho, Ching-Liang, Hsieh, Ruey-Kuen, Vinnyk, Yuriy, Popovych, Oleksandr, Ponomarova, Olga, Bondarenko, Igor, Polishchuk, Iryna, Shah, Riyaz, Mitra, Sanka, Popat, Sanjaykumar, Spicer, James, Toy, Elizabeth, Popat, Sanjaykumar, Talbot, Toby, Brown, Emma, Upadhyay, Sunil, Summers, Yvonne, Gurtler, Jayne, Meza, Luis, and Thropay, John

Published
2016
Full Text
View/download PDF

46. Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16)

Author

Basso, Umberto, primary, Procopio, Giuseppe, additional, Fornarini, Giuseppe, additional, Massari, Francesco, additional, Bearz, Alessandra, additional, Fratino, Lucia, additional, Milella, Michele, additional, Bassanelli, Maria, additional, Ermacora, Paola, additional, Bimbatti, Davide, additional, Verzoni, Elena, additional, Rizzo, Mimma, additional, and Porta, Camillo, additional

Published
2021
Full Text
View/download PDF

50. Abstract LB043: Efficacy of Lorlatinib in Treatment-Naïve Patients (pts) With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in Relation to EML4-ALK Variant Type and ALK Mutations

Author

Bearz, Alessandra, primary, Martini, Jean-François, additional, Jassem, Jacek, additional, Kim, Sang-We, additional, Chang, Gee-Chen, additional, Shaw, Alice, additional, Shepard, Deborah, additional, Dall'O', Elisa, additional, Polli, Anna, additional, Thurm, Holger, additional, Zalcman, Gerard, additional, Campelo, Maria Rosario Garcia, additional, Penkov, Konstantin, additional, Hayashi, Hidetoshi, additional, and Solomon, Benjamin J., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results